$750,000 Breast Cancer Study Grant, Utilizing RPCV Women Fails To Obtain Adequate Data
A $750,000 study designed to examine if taking the malaria prevention drug, chloroquine (Arlen) would reduce the risk of breast cancer among RPCV women did not attract sufficient number of respondents. It is not clear if any further study will be done. The research team needed between 14,000 t0 18,000 participants, but less than 500 RPCV women had responded by May of 2014. The three year study ended in 2015. Background: The Research Team at Baylor College of Medicine in Houston, Texas received the $750,000 grant from the Department of Defense to study, “A Translational Approach to Validate In Vivo Anti-Tumor Effects of Chloroquine on Breast Cancer Risk”. Animal studies had suggested that female mammals who were given chloroquine had a lifetime reduced risk of breast cancer. The grant was awarded to Baylor to investigate if this effect could be found in human females. The Baylor team chose to study RPCV . . .
Read More
No comments yet.
Add your comment